Disclosed are Centryin chimeric antigen receptors (CARTyrins), CARTyrin transposons encoding CARTyrins of the disclosure, cells modified to express CARTyrins of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy. In preferred embodiments, CARTyrins of the disclosure specifically bind to a sequence of prostate specific membrane antigen (PSMA).